Investing Profile

Kevin Bitterman

InvestorVC
Partner at ATLAS VENTURE
atlasventure.comCambridge, Massachusetts
Photo of Kevin Bitterman, Partner at Atlas Venture
Your Intro Paths to Kevin Bitterman

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →

Find Kevin Bitterman on

cb
Current Investing Position
Atlas Venture Partner
Investment Range
$10.0M - $50.0M
Sweet Spot
$25.0M
Investments On Record
43

Kevin Bitterman is on these Sector & Stage Rankings

Kevin Bitterman's Investments On Record (15)

CompanyStageDateRound SizeTotal Raised
Remix Therapeutics
Series UnknownJan 2024$60M
Series BMay 2022$70M
Series ADec 2020$65M
SeedJan 2019$16M
$210M
Co-investors: Michael Rome (Foresite Capital), Leon Chen (The Column Group), Kristina Burow (ARCH Venture Partners), Peter Svennilson (The Column Group)
Mariana Oncology
Series BSep 2023$180M
Series ADec 2021$75M
$250M
Co-investors: Dan Becker (Access Biotechnology), Geert-Jan Mulder (Forbion), Josh Resnick
Curie Therapeutics
Series ADec 2021$75M
$75M
Co-investors: Dan Becker (Access Biotechnology)
Disc Medicine
Series AOct 2019$50M
$260M
Co-investors: Mona Ashiya (OrbiMed), Mark Chin (Arix Bioscience)
Akero Therapeutics
Series BDec 2018$70M
Series AJun 2018$65M
$140M
Co-investors: Aaron Royston (venBio)
Visterra
Series COct 2017$24M
Series CJun 2016$23M
Series BOct 2014$30M
Series ADec 2013$8M
Series ANov 2012$26M
Debt FinancingAug 2010$6M
SeedMay 2009$3M
SeedFeb 2008$2M
$120M
Co-investors: Ling Wong (Highbury Group)
Neuronetics
Series GJun 2017$15M
Series FApr 2015$34M
Series EMay 2011$30M
$170M
Co-investors: Gil Kliman (InterWest), Bruce Cleveland (Wildcat Ventures), Leslie Bottorff (GE Ventures), Liam Ratcliffe (Access Biotechnology)
Morphic Therapeutic
Series AJun 2016$52M
$140M
Co-investors: Vikas Goyal (SR One), Timothy A. Springer